Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

Kifle, Zemene Demelash

doi:10.1016/j.metop.2021.100116

Cited by 15 publications

(12 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 161 , 162 Although the specific mechanisms and pathways are not clear, the use of BTK inhibitors (BTKis) for the treatment of COVID‐19 results in a significant reduction of proinflammatory factors, such as IL‐6, IL‐1, TNFα, as well as relief of excessive inflammatory responses, ARDS, and thrombosis in the lung (reviewed in Refs. 163 and 164 ).…”

Section: Inflammatory Pathways In Covid‐19mentioning

confidence: 98%

“…Therefore, BTKis are beneficial for inflammatory responses, lung injury, thrombosis, and tumors in COVID‐19 patients. 164 Clinically, the BTKis used for COVID‐19 are ibrutinib, acalabrutinib, and zanubutinib. Ibrutinib is a first‐generation BTKi that selectively and irreversibly inhibits BTK regulation of B cells and cytokine release.…”

Section: Intervention Therapymentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions

Jiang

Zhao

Zhou

et al. 2022

MedComm

View full text Add to dashboard Cite

The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis. In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive inflammatory response in patients, causing an inflammatory cytokine storm in severe cases. Cytokine storm leads to acute respiratory distress syndrome, pulmonary and other multiorgan failure, which is an important cause of COVID‐19 progression and even death. Among them, activation of inflammatory pathways is a major factor in generating cytokine storms and causing dysregulated immune responses, which is closely related to the severity of viral infection. Therefore, elucidation of the inflammatory signaling pathway of SARS‐CoV‐2 is important in providing otential therapeutic targets and treatment strategies against COVID‐19. Here, we discuss the major inflammatory pathways in the pathogenesis of COVID‐19, including induction, function, and downstream signaling, as well as existing and potential interventions targeting these cytokines or related signaling pathways. We believe that a comprehensive understanding of the regulatory pathways of COVID‐19 immune dysregulation and inflammation will help develop better clinical therapy strategies to effectively control inflammatory diseases, such as COVID‐19.

show abstract

Section: Inflammatory Pathways In Covid‐19mentioning

confidence: 98%

Section: Intervention Therapymentioning

confidence: 99%

Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions

Jiang

Zhao

Zhou

et al. 2022

MedComm

View full text Add to dashboard Cite

show abstract

“…BTK has a crucial role in multiple signaling pathways, including multiple Toll-like receptors (TLRs), macrophages, and dendritic cells, releasing pro-inflammatory cytokines [103] . BTK also regulates some transcription factors, such as NF-ƙB and IFN-regulatory factors, which are imperative for macrophage M1 polarization and subsequent production of several inflammatory cytokines, chemokines, and phagocytosis [15] , [43] , [73] . The BTK pathway is up-regulated in pro-inflammatory macrophages and activates downstream signaling pathways.…”

Section: Brutton's Tyrosin Kinase (Btk) Inhibitormentioning

confidence: 99%

“…Besides, no toxicities were observed via using BTK inhibitors [79] . Although it is unclear how lymphopenia affects the severity of COVID-19, numerous studies show that lymphopenia is strongly associated with CRS in COVID-19 [43] .…”

Section: Brutton's Tyrosin Kinase (Btk) Inhibitormentioning

confidence: 99%

Recent clinical findings on the role of kinase inhibitors in COVID-19 management

Malekinejad¹,

Baghbanzadeh²,

Nakhlband³

et al. 2022

Life Sciences

View full text Add to dashboard Cite

“…The tyrosine kinase receptor anaplastic lymphoma kinase (ALK) has been linked to the development of many tumours. Clinical studies on another PTK, Bruton tyrosine kinase (BTK) inhibition revealed the ameliorating cancer in SARS-CoV-2 patients ( Kifle, 2021 ). Again, for the treatment of patients with chronic lymphocytic leukaemia (CLL) and haematological malignancies (HM), BTK inhibitor like ibrutinib is the most advanced in clinical development ( Aalipour and Advani, 2014 ; Wang et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Target Specific Inhibition of Protein Tyrosine Kinase in Conjunction With Cancer and SARS-COV-2 by Olive Nutraceuticals

Ghosh

Mukerjee²,

Sharma³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

The fact that viruses cause human cancer dates back to the early 1980s. By reprogramming cellular signaling pathways, viruses encoded protein that can regulate altered control of cell cycle events. Viruses can interact with a superfamily of membrane bound protein, receptor tyrosine kinase to modulate their activity in order to increase virus entrance into cells and promotion of viral replication within the host. Therefore, our study aimed at screening of inhibitors of tyrosine kinase using natural compounds from olive. Protein tyrosine kinase (PTK) is an important factor for cancer progression and can be linked to coronavirus. It is evident that over expression of Protein tyrosine kinase (PTK) enhance viral endocytosis and proliferation and the use of tyrosine kinase inhibitors reduced the period of infection period. Functional network studies were carried out using two major PTKs viz. Anaplastic lymphoma kinase (ALK) and B-lymphocytic kinase (BTK). They are associated with coronavirus in regulation of cell signaling proteins for cellular processes. We virtually screened for 161 library of natural compounds from olive found overexpressed in ALK and BTK in metastatic as well as virus host cells. We have employed both ligand and target-based approach for drug designing by high throughput screening using Multilinear regression model based QSAR and docking. The QSAR based virtual screening of 161 olive nutraceutical compounds has successfully identified certain new hit; Wedelosin, in which, the descriptor rsa (ratio of molecular surface area to the solvent accessible surface area) plays crucial role in deciding Wedelosin’s inhibitory potency. The best-docked olive nutraceuticals further investigated for the stability and effectivity of the BTK and ALK during in 150 ns molecular dynamics and simulation. Post simulation analysis and binding energy estimation in MMGBSA further revealed the intensive potential of the olive nutraceuticals in PTK inhibition. This study is therefore expected to widen the use of nutraceuticals from olive in cancer as well as SARS-CoV2 alternative therapy.

show abstract

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

Cited by 15 publications

References 106 publications

Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions

Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions

Recent clinical findings on the role of kinase inhibitors in COVID-19 management

Target Specific Inhibition of Protein Tyrosine Kinase in Conjunction With Cancer and SARS-COV-2 by Olive Nutraceuticals

Contact Info

Product

Resources

About